NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.

News

  1. New publication from the GlioME Team and the national POLA network (dedicated to high grade oligodendroglioma) pointing at CDKN2A homozygous deletion as a strong adverse prognostic factor in diffuse malignant IDH-mutant gliomas.

    In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).

    We showed that:
    - CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.

    - Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.

  2. INP & Vect-Horus first day off in Black Stone pub

    On thursday december the 12th, most of INP and Vect-Horus members got together and spent a day in the Black Stone pub, Marseille, to celebrate the fact that nearly two years after its creation, the Institute of NeuroPhysiopathology is finally located on Tmone Campus.

  3. Michel KHRESTCHATISKY invited to the third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by DHUNE and NeurATRIS
  4. Maeva MONTALEYTANG and Noé DUMAS from the GlioME team presented their research on nanoparticles at the SFNano C'Nano congress

    Maeva and Noé presented their poster at the SFNano C'Nano conference entitled "Preclinical evaluation of a paclitaxel nanoprodrug for glioblastoma therapy".

  5. Un nouvel arrivant dans l'équipe 5

    L'équipe 5 a le plaisir d'accueillir en stage du 1er décembre 2019 au 31 mars 2020, Théo Loignon étudiant à l'école d'ingénieur de Bordeaux ei.cesi. Théo travaillera avec Jean-Philippe Dales sur l'imagerie chimique du tissu nerveux au cours de la neuroinflammation.

  6. New publication for the Neuro-inflammation and Multiple Sclerosis team (INP team 5) in Cytokine about the immunomonitoring of infliximab biotherapies

    In this paper, Daniel Bertin evaluated the immunological follow-up of patients suffering from chronic inflammatory diseases and receiving anti-TNF biotherapy. Three commercial ELISA assays for monitoring soluble through levels of infliximab and anti-infliximab antibodies in serum showed a good global correlation of results. However, some quantitative discrepancies could change clinical decision. As a consequence, Daniel Bertin recommended to keep the same kit to perform a longitudinal follow-up of patients.

  7. Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response" .

    Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".

    Subsequently she was interviewed by :
    France 3  (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ; 
    Provence Azur (18/11/2019) ;
    20 Minutes Marseille (18/11/2019)
    - La Provence

     

  8. DESU « Exploration et traitement des maladies auto-immunes »

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response" .

Aurélie Tchoghandjian-Auphan, CRCN CNRS from the GlioME team, in the Insitute of NeuroPhysiopathology, UMR CNRS 7051, was recently granted by ARC fondation for her project "Effects of Smac mimetics treatment on glioblastomas immune response".

Subsequently she was interviewed by :
France 3  (JT 19/20 PACA diffusion du 15/11: 7'09 à 9'45) ; 
Provence Azur (18/11/2019) ;
20 Minutes Marseille (18/11/2019)
- La Provence

 

Undefined

GlioME team in collaboration with INT (Institute of Neurosciences Timone) published a new study in Journal of Neuroinflammation on the effect of Bevacizumab on glioblastoma-bearing mice, using 2-photon imaging

Our data show that VEGF blockade leads to an increased recruitment of monocytes and to an adjustment of dendritic cell subsets’ profiles, differing in their ability to induce an adaptive immune response. Altogether, they provide important new insights into the effects of Bevacizumab at the cellular level and into the spatio-temporal evolution of intra-tumoral innate immune cell densities.

Undefined

Marseille - Cassis 2019

Congratulations to all the CNRS team for running the Marseille-Cassis race two weekends ago, and especially to Claude Villard (7th from the left, top row), INP team 9 and PINT facility member who ran this semi-marathon in 1 hour and 48 minutes.

Next year, let's make a whole INP team (as usual, the race will take place on the last Sunday of October)!

For more information, head to the race's official website.

Undefined

Listening to our molecular clocks

During the NeuroStories event, held on Monday October 7 at the Faculty of Medicine, Anne-Marie François Bellan gave a remarkable stand up on how our body vibrates to the rhythm of internal chronometers called circadian clocks. She also explained how the molecular clock uses small corpuscles and cell space to make our genes rhythm.

Click on the news to  see the video of her brilliant speech.

 

 

 

 

English
Anne-Marie François Bellan

Prof. D. Figarella-Branger, who belongs to the cIMPACT-NOW Working Committee, attended to the last meeting of the consortium in Utrecht (16-17 september).

The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW  was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.

Undefined

Three members of INP presented their work on Glioma during the 14th EANO annual meeting held in Lyon (19 - 22 September, 2019)

During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat

Undefined

Nadia Merad Coliac and Maxime Bonnet joined the NOSE team

Nadia Merad Coliac, plastic designer, joined the NOSE (Nasal Olfactory Stemness and Epigenesis) team, as an Associate researcher. At the crossroads of several disciplines, she develops an experimental work of art and science, in the field of bioluminescence. She is considering a therapeutic application in patients with autism spectrum disorders (ASD). Recently, Nadia published Lumière vivante - Théorie et pratique de la bioluminescence (Living light - theory and use of bioluminescence) - L’Harmattan eds.

English

New publication from the GlioME Team (INP team 8) in Cancers pointing at A2B5 as an attractive therapeutic target for glioblastomas.

Partners